Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: Megan Daly, MD; Other
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Glaucoma
Interventions: Ranibizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Interstitial Lung Disease
Interventions: Not listed
Lead sponsor: Pulmonary Care and Research Collaborative Limited; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Interstitial Lung Diseases
Interventions: Not listed
Lead sponsor: Pulmonary Care and Research Collaborative Limited; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: bevacizumab, Erlotinib; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more

Conditions: Interstitial Lung Disease
Interventions: Not listed
Lead sponsor: Pulmonary Care and Research Collaborative Limited; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HER2-positive Breast Cancer
Interventions: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Beverly Hills, California • San Francisco, California • Stanford, California + 9 more

Conditions: Joint Bleed, Hemophilia A
Interventions: handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform; Device
Lead sponsor: Washington Institute for Coagulation; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Influenza, Respiratory Viral Infection
Interventions: Point-of-care molecular testing and treatment of influenza; Combination Product
Lead sponsor: University of Washington; Other
Eligibility: 3 Months and older
Enrollment: 1,618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Burien, Washington • Seattle, Washington

Conditions: Non-Hodgkin's Lymphoma
Interventions: Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
Interventions: GDC-0853; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 7
States / cities: Stanford, California • St Louis, Missouri • Columbus, Ohio + 4 more

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Pulmonary Care and Research Collaborative Patient Registry

Monitoring and Evaluation Study of Project ECHO for ILD

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Patient-Reported Outcome Study of Project ECHO for ILD

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

Handheld Ultrasound (HHUS) for Home Use in Hemophilia

Test-and-treat for Influenza in Homeless Shelters

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

About this Genentech, Inc. sponsor directory page